Objective : A retrospective review of premedication method and drug resistance of aspirin and clopidogrel in association with thromboembolic events during and after coil embolization of an unruptured intracranial aneurysm was conducted.
Methods : Our premedication policy for coil embolization of an unruptured intracranial aneurysm has changed from administration of the loading dose before the procedure (i.e. loading group) to repeated administration of the maintenance dose for several days (i.e. preparation group). The loading group (27 patients with 29 aneurysms) and the preparation group (30 patients with 35 aneurysms) were compared for identification of the effect of premedication method on periprocedural thromboembolic events. The results of drug response assays of the preparation group were analyzed with respect to periprocedural thromboembolic events.
Results : No statistically significant difference in incidence of thromboembolic events was observed between the loading group and the preparation group. Analysis of the results of the drug response assay showed high prevalence (56.7%, 73.3%) of clopidogrel resistance and relatively low prevalence (6.7%) of aspirin resistance. Patients who had thromboembolic events tended to have lower responsiveness to both aspirin and clopidogrel than patients without it.
Conclusion : The method of antiplatelet premedication does not affect the rate of periprocedural thromboembolic events in coil embolization for treatment of an unruptured intracranial aneurysm. Nevertheless, considering the high prevalence of drug resistance, it is reasonable to premedicate antiplatelet agents in the preparation method for the drug response assay. Use of a higher dose of aspirin and clopidogrel or addition of an alternative drug (cilostazol or triflusal) can be applied against antiplatelet agent resistance. However, because the hemorrhagic risk associated with this supplementary use of antiplatelet agent has not been well-documented, the hemorrhagic risk and the preventive benefit must be weighed.
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INTRODUCTION
The incidence of overall complication during elec-tive coil embolization for treatment of unruptured aneurysms is low. 26) Thromboembolic events account for the majority of complications, with a reported incidence of 3.4-6.2%. 7)11)27) Antiplatelet agent premedication has been proposed for reducing thromboembolic risk, and the current evidence supports this preventive usage.
3)7)11)
Aspirin and clopidogrel have been widely used for antiplatelet premedication for endovascular procedures. 4) Responsiveness to both drugs is quite variable, and there is a group of patients who exhibit low responsiveness to these two drugs. Several studies have reported a prevalence of drug resistance of 5.5-60% for aspirin and 5-44% for clopidogrel.
4)5)25)
Two methods for premedicating antiplatelet agents have been used; one is dosing the drugs for several days until the steady drug level is achieved and the other is to load a high-dose of the drugs before the procedure. The former can be described as a 'preparation method', while the latter can be called a 'loading method'. Little has been reported regarding the effects of these two premedication methods in the context of coil embolization for treatment of an unruptured aneurysm. In this study, we attempted to compare the difference in periprocedural thromboembolic events between the preparation method, in which patients take aspirin and clopidogrel for several days, and the loading method, in which patients take a high dose of aspirin and clopidogrel before the procedure.
Patients in the preparation group underwent drug response assays of clopidogrel and aspirin before the procedure. We analyzed the results of these drug response assays in relation to the periprocedural thromboembolic events. Literature on antiplatelet agent resistance was reviewed in the search for proper treatment for aspirin and clopidogrel resistance. In order to rule out the risk of stent insertion per se, patients who underwent stent-assisted coil embolization were excluded. Because it could be a significant independent risk factor, patients with a history of ischemic stroke and/or a higher than moderate degree of stenosis in any of the intracranial arteries and carotid arteries were also excluded. There were two intra-procedural ruptures of aneurysm, which were excluded, considering that vasospasm could be an interfering factor. Patients in both groups who were on antiplatelet therapy other than aspirin and clopidogrel were excluded, and, in order to avoid compounding by existing antiplatelet effects, patients who were already on aspirin, clopidogrel, or both were excluded from the loading group. Ultimately, 30 patients with 35 intracranial aneurysms were included in the preparation group, and 27 patients with 29 aneurysms were included in the loading group.
MATERIALS AND METHODS

Subjects
Thromboembolic events were categorized according to either radiological events or symptomatic events.
Thrombus formation during the procedure, or any In the preparation group, drug response assays for aspirin and clopidogrel were performed using the VerifyNow® system (Accumetrics, San Diego, CA).
Aspirin reaction unit (ARU) was measured by
VerifyNow® Rapid platelet function assay-aspirin and were compared using the Mann-Whitney test.
Fisher's exact test or chi-square test was used for processing of categorical data. Statistical significance was defined as 'p < 0.05'. A summary of the results of antiplatelet response assays is shown in Table 3 . Although the prevalence of aspirin resistance was 6.7%, the prevalence of clopidogrel resistance was remarkably high (56.7%, 73.3%).
RESULTS
A summary of the basic characteristic of patients
Every patient with aspirin resistance also showed resistance to clopidogrel. Suboptimal response to aspirin, which can be estimated from ARU ranging between 500 and 550, was found in three patients and two of them also had low responsiveness to clopidogrel.
Results of analysis of the relationship between the thromboembolic event and responsiveness to aspirin and clopidogrel are shown in Table 4 . Patients who had a thromboembolic event had higher ARU than patients who did not have a thromboembolic event 
DISCUSSION
As a supplement to intraprocedural anticoagulation, which has been almost standardized in all types of coil embolization-related procedures for thromboembolic risk reduction, premedication with antiplatelet agent has at first been adopted to the stent-assisted coil embolization from coronary stenting, considering its beneficial effects. In short, the benefit of antiplatelet premedication in the conventional coil embolization has not been proved; therefore, since it cannot be fully estimated before the procedure whether conventional coil embolization will be possible and the complication rate of antiplatelet agent premedication is acceptably low, it is reasonable to premedicate the entire population of patients undergoing coil embolization.
7)11)
In our institute, due to concerns regarding hemorrhagic events, which can be fatal with high frequency, there was a reluctance to employ antiplatelet agent before the endovascular procedures. We began antiplatelet agent premedication with the stent-assisted coil embolization. We only employed antiplatelet agent for stent-assisted procedures and aspirin with clopidogrel was given orally for three days before the procedure, referring to the guideline report of stent-assisted coil embolization. The length of time during which platelet function is compromised can be recognized as a cumulative risk for hemorrhagic event in patients with intracranial aneurysm. In order to minimize the duration of exposing patients to compromised platelet aggregation, we first employed antiplatelet agents using the loading method. Then, resistance to antiplatelet agents became an issue; therefore, we changed our policy of antiplatelet agent premedication to the preparation method, which was adopted from that of stent-assisted coil embolization. In this way, using the drug response assays, we were able to screen out patients with resistance to antiplatelet agents, and deal with the risk. 
